N/A(healthy adults)
Conditions
Interventions
Test food A
Take a hyper protect capsules which contain Bifidobacterium in a package. (Single ingestion)
Test food B
Take a Bifidobacterium in a package. (Single ingestion)
Sponsors
Morishita Jintan Co., Ltd.
Animal Function Science Laboratory, Department of Applied Biological Sciences, Faculty of Agriculture,Setsunan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Healthy men and women of 20 years or older at the time of consent acquisition (2) The number of Bifidobacterium spp. (3) Person who the number of defecation per day is less than three times on average (4) Persons with stool characteristics (Bristol scale) 3 or 4 (5) BMI has a standard range (18.5-25) (6)A person who receives the explanation of the clinical trial in advance, understands the contents, agrees to the purpose, and obtains written consent from the person
Exclusion criteria
Exclusion criteria: (1) Those who underwent open surgery within half a year of the trial start (2) Those who have taken antibiotics for more than one week within half a year of the study start (3) Persons who are allergic to the test food (4) Those who plan to change their lifestyle significantly during the examination period (5) Persons who are chronically prone to diarrhea (meaning stools with mud or watery stools) (6) Patients with a history of significant liver dysfunction, renal dysfunction, or cardiovascular disease that is considered inappropriate for this study (7) A person suspected of having a chronic or acute infection (8) Those who are pregnant or nursing or who may be pregnant (9) Those who participated in other clinical trials within the past 1 month (10) Others who were judged by the study investigator to be inappropriate for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of ingested viable probiotic bacteria that reached to colon. : The fecal number of viable bacteria ingested (Bifidobacterium) | — |
Secondary
| Measure | Time frame |
|---|---|
| Analysis on gut microbiota by 16S metagenomic analysis : Evaluation of the abundance of Bifidobacterium spp. in the feces | — |
Countries
Japan
Contacts
Public ContactMamiko Kohno
Morishita Jintan Co., Ltd. Health Care Product Department
Outcome results
None listed